Literature DB >> 11268427

Immunoendocrinologic abnormalities in human immunodeficiency virus infection.

M Clerici1, M Galli, S Bosis, C Gervasoni, M Moroni, G Norbiato.   

Abstract

Alterations in the production of adrenal steroids and a complex pattern of dysregulation in cytokine profiles accompany the progression of HIV infection. Cortisol levels increase in HIV infection, while those of dehydroepiandrosterone (DHEA), a physiologic antagonist of the immunoregulatory activities of cortisol, decrease. A shift from type-1 to type-2 cytokine production is also detected in most patients during disease progression. This shift is summarized as a defective production of interferon gamma (IFN gamma), interleukin-2 (IL), and IL-12 accompained by increased production of IL-4, IL-5, IL-6, and IL-10. IFN gamma and IL-2 are suppressed, while the generation of IL-4 is stimulated by cortisol and pharmacological doses of glucocorticoids (GC). GC and IL-4 stimulate the differentiation of B lymphocytes into IgE-producing plasma cells, the concentration of which augments in HIV infection. Finally, GC induces programmed cell death (PCD) in a variety of different cells, including mature T lymphocytes. Because (1) TH1 but not TH2 undergo rapid Fas-mediated PCD upon antigen-stimulation, and (2) TH2 clones preferentially survive in vitro cell cultures, the progressive shift from type-1 to type-2 cytokine production observed in HIV infection could be at least partially provoked by the increase in the production of cortisol and the reduction of DHEA. Progression of HIV infection to AIDS can be controlled by highly active antiretroviral therapy (HAART); HAART drastically reduces HIV plasma viremia, but is less effective in immune reconstitution. Additionally HAART is associated in a sizable portion of patients by complex lypodistropyc phenomena that often involve the endocrine system.

Entities:  

Mesh:

Year:  2000        PMID: 11268427     DOI: 10.1111/j.1749-6632.2000.tb05462.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.

Authors:  Marni N Silverman; Brad D Pearce; Christine A Biron; Andrew H Miller
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

2.  Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.

Authors:  Emma Tippett; Wan-Jung Cheng; Clare Westhorpe; Paul U Cameron; Bruce J Brew; Sharon R Lewin; Anthony Jaworowski; Suzanne M Crowe
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

3.  HIV-1 clade C infection and progressive disruption in the relationship between cortisol, DHEAS and CD4 cell numbers: a two-year follow-up study.

Authors:  Seetharamaiah Chittiprol; Adarsh M Kumar; K Taranath Shetty; H Ravi Kumar; P Satishchandra; R S Bhimasena Rao; V Ravi; A Desai; D K Subbakrishna; Mariamma Philip; K S Satish; Mahendra Kumar
Journal:  Clin Chim Acta       Date:  2009-07-01       Impact factor: 3.786

4.  PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.

Authors:  Adriano Boasso; Andrew W Hardy; Alan L Landay; Jeffrey L Martinson; Stephanie A Anderson; Matthew J Dolan; Mario Clerici; Gene M Shearer
Journal:  Clin Immunol       Date:  2008-07-22       Impact factor: 3.969

5.  Physiological correlates of HIV-related fatigue.

Authors:  Julie Barroso; Brian Wells Pence; Naima Salahuddin; James L Harmon; Jane Leserman
Journal:  Clin Nurs Res       Date:  2008-02       Impact factor: 2.075

Review 6.  Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs.

Authors:  Sébastien Pasquereau; Amit Kumar; Georges Herbein
Journal:  Viruses       Date:  2017-03-30       Impact factor: 5.048

7.  The relationship of hair glucocorticoid levels to immunological and virological outcomes in a large cohort of combination antiretroviral therapy treated people living with HIV.

Authors:  Quan Zhang; Shuaifeng Liu; Xiaoming Li; Shan Qiao; Yuejiao Zhou; Zhiyong Shen
Journal:  BMC Infect Dis       Date:  2022-03-20       Impact factor: 3.090

8.  Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?

Authors:  Carlo Contoreggi; George P Chrousos; Michele Di Mascio
Journal:  Neurobehav HIV Med       Date:  2016-12-28

Review 9.  Do Dehydroepiandrosterone (DHEA) and Its Sulfate (DHEAS) Play a Role in the Stress Response in Domestic Animals?

Authors:  Gianfranco Gabai; Paolo Mongillo; Elisa Giaretta; Lieta Marinelli
Journal:  Front Vet Sci       Date:  2020-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.